Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
Trial ID or NCT#
The purpose of the study is to determine whether standardized implementation of a scripted template for discussing important issues that arise near the end of life improves the care of those who have advanced cancer.
A Randomized, Controlled Trial Examining the Use of The "Serious Illness Conversation Guide" (SICG) in Patients With Advanced Gastro-Intestinal Cancers
- - Patients with metastatic colorectal cancer whose tumor has progressed on both FOLFOX and FOLFIRI. - Exception: Patients with metastatic colorectal cancer whose tumors demonstrate a BRAF V600E mutation may be enrolled regardless of prior chemotherapy. - Exception: Patients whose tumors are MSI-H must have experience progression through immunotherapy in addition to the therapies mentioned above. - Patients with metastatic pancreatic adenocarcinoma. - Patients with metastatic gastric or esophageal cancer whose tumor has progressed through first-line chemotherapy of any type. - Patients with metastatic cholangiocarcinoma whose tumor has progressed through first-line chemotherapy of any type. - Patients with metastatic hepatocellular carcinoma whose tumor has progressed through PD1 blockade. - Patients with metastatic high-grade neuroendocrine tumor. - A patient with a metastatic GIST that has progressed through first-line tyrosine kinase inhibitor. - Expected life expectancy of at least one month
- - Any patient not meeting the above criteria - Non-English speaking patients
Contact us to find out if this trial is right for you.